Michel, L. L., Wallwiener, M., & Schneeweiss, A. (2025). Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer. European journal of cancer, 227, . https://doi.org/10.1016/j.ejca.2025.115689
Chicago-Zitierstil (17. Ausg.)Michel, Laura L., Markus Wallwiener, und Andreas Schneeweiss. "Prognostic Impact of the Choice of Chemotherapy After First-line CDK4/6 Inhibitor Therapy in Patients with Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer." European Journal of Cancer 227 (2025). https://doi.org/10.1016/j.ejca.2025.115689.
MLA-Zitierstil (9. Ausg.)Michel, Laura L., et al. "Prognostic Impact of the Choice of Chemotherapy After First-line CDK4/6 Inhibitor Therapy in Patients with Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer." European Journal of Cancer, vol. 227, 2025, https://doi.org/10.1016/j.ejca.2025.115689.